niﬁcantly improved glycemic control inpatients with type 2 diabetes and was as-sociated with signiﬁcant sustained weightloss when added to the commonly usedcombination of metformin and sulfonyl-urea. The main adverse events were dose-dependent nausea and mild to moderatehypoglycemia that was ameliorated by ap-propriate adjustments of sulfonylureadosage. This novel therapy may offer an-other potential treatment option whentwo-drug oral therapy fails to maintainadequate glycemic control. Acknowledgments — This report was sup- ported by Amylin Pharmaceuticals, San Diego, California, and Eli Lilly, Indianapolis, Indiana. The authors thank the Exenatide-115 Clin-